Although PF-3758309 was initially developed as a PAK4 inhibitor, which plays an essential role in oncogenic signaling pathways [18], our results demonstrate that its anti-tumor effects extend beyond PAK4 inhibition. Here, PAK4 is linked to neoplasm.